Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | PKLR | P30613 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12792906 | 0.83 | KMT2A (0.61) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL23052287 | 0.78 | TDP1 (0.65) | TDP1SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL16221401 | 0.77 | TDP1 (0.76) | TDP1SMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL23051998 | 0.77 | TDP1 (0.75) | TDP1SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL23045594 | 0.75 | TDP1 (0.72) | TDP1SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL1200727 | 0.75 | ALDH1A1 (0.81) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL23052368 | 0.74 | TDP1 (0.70) | TDP1SMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL26212953 | 0.73 | PKM (0.59) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL23052427 | 0.72 | TDP1 (0.67) | TDP1SMN1; SMN2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL22187771 | 0.72 | HPGD (0.71) | SMN1; SMN2ALDH1A1LMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | TDP1 3072/4885SMN1; SMN2 4780/4885ALDH1A1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.